Healthtech startup Mykare has closed a $3.2M seed round — including a $1M top-up finalised on June 29, 2026 — to accelerate its agentic AI and voice platform for clinics and hospitals, as publicly reported. The round drew participation from Andrew Parker and Alfredo Vaamonde, co-founders of Papa.com, alongside a Middle Eastern family office, marking a notable cross-border endorsement of the company’s technology direction.
Quick Highlights
- Participating Investors: Andrew Parker and Alfredo Vaamonde (co-founders, Papa.com); Middle Eastern family office
- Investor Background: Parker and Vaamonde built Papa.com, a US-based platform connecting older adults with companionship and care support
- Headquarters: India, with active operations across India, US, UK, and Middle East
- Announcement Date: June 29, 2026
Funding Breakdown
Use of Funds
Capital from this round will be directed toward scaling Mykare’s agentic AI and voice AI platform, built to serve clinics and hospitals. The platform targets small-and-medium-sized healthcare providers — a segment that has historically been underserved by enterprise-grade clinical software.
Funding Timeline
The total seed round stands at $3.2M. The most recent tranche — a $1M top-up — was formally closed on June 29, 2026, bringing the seed round to its final close.
Expansion Plans
Mykare is currently active across 30 or more hospitals and clinics spanning India, the US, the UK, and the Middle East. The company reports a waiting list of more than 20 additional healthcare providers, signalling early demand traction ahead of a broader commercial rollout.
Significance
Mykare’s trajectory represents a deliberate pivot: the company moved away from a B2C hospital-referral model and repositioned itself as an AI-infrastructure layer for SMB clinics — a far larger and less contested market. The involvement of Papa.com’s co-founders is strategically telling; having built a care-coordination platform in the US, Parker and Vaamonde bring both domain credibility and a potential network effect for Mykare’s international expansion. For India’s healthtech sector, the deal illustrates that AI-native clinic tools are attracting global operator-investors, not just traditional venture capital. With a live waitlist and four active geographies, the company’s near-term challenge will be converting early deployments into durable, recurring revenue.
These details have been verified against multiple publicly available reports as of June 29, 2026.
Stay current with the latest startup funding news on The Courtroom.
Disclaimer: This report is compiled from publicly available sources and is for informational purposes only; funding figures are as publicly reported and may be subject to change.
